The odyssey continues:

A 'deep dive' into NI's 100k Genomes Project undiagnosed.

C McKenna¹, K Kerr², D Thomas², S Heggarty¹, W Wright¹, R Martin¹, P Hart¹, G Rea¹, L Soeters¹, C Flanagan², S McKee¹, AJ McKnight² 1. Northern Ireland Regional Molecular Diagnostics Service, Belfast Health & Social Care Trust, 2. Queen's University Belfast

Artist: Dr Shane McKee

DIAGNOSIS

The back story...

- 100,000 genomes project
- NIRMDS recruited 442 probands
- GEL tiering system
 - Clinician review of tier 1 & 2
 - Formal classification by local clinical scientists
- Diagnostic yield 18.5% (n=82)



Pass in the healthy population	
Kare in the healthy population	
Protein altering in at least one transcript	
Follow the relevant mode of inheritance (PanelApp) No Tier n	ull
Segregate appropriately within the family	
Ves Ves	
Is the variant in a Green gene on a PanelApp panel No Tier applied to the participant?	3
Yes	
Protein altering Tier	2
What is the most severe	
predicted consequence of the	
variant? Protein truncation Tier	1
Denovo	

What we are doing...

- 360 probands remained undiagnosed...
- 100KGP top 5 exomiser variants
- Relevant data collated
 - Inheritance, OMIM morbidity, gnomAD prevalence, REVEL score, missense constraint and pLI.
- Clinician review, of variants & phenotype
- Formal classification by clinical scientists & discussion at Genomics MDT





3/7

EXOMISER TOP 5 (SNVs)

Exemiser.	Variant co-ordinates1	Gene (transcript) (HGVS)	Zygosity.	(gosity Inheritance (if known)	<u>Qmim</u> Morbid	GnomAD exome+genome	No. of gnomAD exome/genome	Missense variants only		Null variants only ⁴
	Туре				Y/N	AC ²	homozygotes ³	REVEL score ^s	GnomAD Z-score ⁷	GnomAD pLI ⁶
1	4:968279:C:T SNV splice_region_variant	DGKQ(NM 001347.4):c.663+3 G>A	Het	De novo	N	2199	0	n/a	n/a	0
2	X:48560533:C:T SNV missense_variant	TBC1D25(ENST00000376771.9) :c.1625C>T (p.Pro542Leu)	Hemi	Mat	N	9	o	0.05999	3.1	n/a
3	22:31267899:C:T SNV missense_xatiant Compound Heterozygous	LIMK2(ENST00000331728.9):c. 1252C>T (p.Arg418Cys)	Het	Mat	N	67	o	0.6179	1.4	n/a
3	22:31266023:G:A SNV Dissense_xatiant Compound Heterozygous:	LIMK2(ENST00000331728.9):c. 932G>A (p.Arg311His)	Het	Pat	N	1	o	0.6679	1.4	n/a
4	17:18278287:C:T SNV Dissense_xatiant Compound Heterozygous	TOP3A(NM 004618.5):c.2215G <u>>A</u> (p.Gly739Arg)	Het	Mat	Y	211	0	0.4399	1.31	n/a
4	17:18278232:G:A SNV Dissease_xatiant Compound Heterozygous	<u>TOP3A(NM 004618.5):c.2270C</u> <u>>T</u> (p.Pro757Leu)	Het	Pat	Y	700	1	0.03599	1.31	n/a
5	20:62326876:C:T SNV Missense_xatiant Compound Heterozygous	LAMA5(NM_005560.6):c.5203 G>A (p.Val1735Met)	Het	Mat	N	2140	9	0.4219	-0.27	n/a
5	20:62324168:G:A SNV missease_xatiant Compound Heterozygous	LAMA5(NM_005560.6):c.5680 <u>C>T</u> (p.Arg1894Cys)	Het	Pat	N	285	Not reported	0.286	-0.27	n/a

4 D.-314 (14-50

What we have found so far...

- 200/360 probands top 5 exomiser variants reviewed
 - >1,000 variants

- Potential causative variants in 42 patients (21%)
 - 13 formal classification
 - 6 likely pathogenic / pathogenic
 - 7 hot VUS

Why were they "missed" in tier 1/2...

- HPO terms 'incomplete' / too narrow
- New gene disease association has emerged / is emerging
- X-linked variants in females
- Variants dismissed by clinician
- Variant inherited from "unaffected" parent / not shared with "affected sibling"

5 key lessons learned...

- 1. Comprehensive phenotyping is key
- 2. Variant 1st, phenotype 2nd

7/7

- 3. One eye on the patient, one eye on the data
- 4. Filtering by inheritance is dead, prioritisation is King
- 5. Access to functional work is imperative